SCHEMBL15042597

SCHEMBL15042597

COc1ccc(CCCCCOc2ccc(CNCCCO[PH](=O)O)cc2-c2ccco2)cc1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
HPGD P15428 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
KDM4E B2RXH2 1/20 0.38
S1PR2 O95136 2/20 0.38
S1PR1 P21453 2/20 0.38
S1PR3 Q99500 2/20 0.38
LPAR2 Q9HBW0 2/20 0.38
SCN8A Q9UQD0 1/20 0.38
SLC2A1 P11166 1/20 0.38
TP53 P04637 1/20 0.37
HTR1A P08908 1/20 0.37
HTR7 P34969 1/20 0.37
HTR6 P50406 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15042634 0.93 CHRM2 (0.43) ALDH1A1POLBMEN1KMT2AKDM4E
SCHEMBL15042607 0.91 ALDH1A1 (0.39) ALDH1A1POLBMEN1KMT2AKDM4E
SCHEMBL15042476 0.90 S1PR2 (0.37) ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL15042486 0.90 KMT2A (0.39) ALDH1A1HPGDPOLBMAPTSMN1; SMN2
SCHEMBL15042514 0.90 S1PR2 (0.42) ALDH1A1POLBMAPTSMN1; SMN2MEN1
SCHEMBL15042484 0.90 S1PR2 (0.42) ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL15042553 0.89 ALDH1A1 (0.36) ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL15042586 0.88 KDM4E (0.39) ALDH1A1POLBKDM4ES1PR2S1PR1
SCHEMBL15042524 0.86 CHRM2 (0.40) POLBMEN1KMT2AKDM4ES1PR2
SCHEMBL15042532 0.86 KMT2A (0.39) ALDH1A1MEN1KMT2AKDM4ES1PR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8828973-B2 Compounds as receptor modulators with therapeutic utility ALLERGAN, INC. (US) 2014-09-09 US disclosed
US-20140221317-A1 NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY ALLERGAN, INC. (US) 2014-08-07 US disclosed
US-8741875-B2 Compounds as receptor modulators with therapeutic utility ALLERGAN, INC. (US) 2014-06-03 US disclosed
US-20130157982-A1 NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY ALLERGAN, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221317-A1 NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY S1PR1, S1PR3, S1PR2 ALDH1A1 3552/4885HPGD 2878/4885L3MBTL1 4805/4885
US-20130157982-A1 NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY S1PR1, S1PR3, S1PR2 ALDH1A1 3552/4885HPGD 2878/4885L3MBTL1 4805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.